Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M

Chemours Co

2025-FY EPS reported -$2.57 revenue$5,808,000,000

Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
Q4 adjusted EBITDA $128M vs $168M YoY; net sales $1.3B slightly down; TSS segment record Q4 with 37% Opteon revenue growth.
Full year 2025 net loss $386M (-$2.57/diluted) vs net income $69M ($0.46) prior year; adjusted net income $143M ($0.95) vs $179M ($1.19).
Full year 2026 outlook: net sales growth 3-5%, adjusted EBITDA $800-$900M, free cash flow conversion above 25%.
Announced sale of former Kuan Yin TiO2 site for ~$300M net proceeds on Jan 15, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.